Background and aim: In Mexico, there is a high prevalence of patients with hepatitis C virus (HCV) with chronic kidney disease on hemodialysis (CKD-H); since the appearance of new direct-acting antivirals (DAAs), 95-99% of patients have been documented to be cured worldwide, however, in a mexican population with these characteristics, there are no studies that support the response to treatment. The objective was to determine the sustained viral response (SVR) and drug safety in patients with HCV and CKD-HD treated with DAAs free of sofosbuvir in patients at UMAE 71.
Material and methods: Observational and retrospective study that including patients over 18 years old with HCV diagnosed by positive RNA test using CRP technique, who also had permanent CKD-HD received at UMAE 71. Twenty-eight patients were included, of whom 25 received glecaprevir/pibrentasvir for 8 weeks and 3 received ombitasvir/paritaprevir/ritonavir/dasabuvir for 12 weeks; all completed treatment. SVR was considered negative CRP 12 weeks after treatment was completed; in addition, treatment-related adverse effects were documented. Statistical analysis was based on frequencies and percentages, means and standard deviation.
Results: The patients were analyzed from February 2019 to January 2020. The baseline characteristics of the patients are shown in Table 1. SVR was documented at 12 weeks of 100% and they presented minimal side effects.
Baseline Characteristics of the Patients.
| Characteristics | Glecaprevir/PibrentasvirTotal (n=25) | Ombitasvir/paritaprevir/ritonavir/ dasabuvirTotal (n=3) |
| Sex: Women-Men (%) | 52%-48% | 100% (M) |
| Age (years) | 57.8±16.4 | 52.6±17.6 |
| Diabetes mellitus (%) | 40% | 33.3% |
| Systemic arterial hypertension (%) | 96% | 100% |
| Genotype 1B (%) | 96% | 100% |
| Non-significant fibrosis (FIB4 F1-F2) (%) | 68% | 66.6% |
| Significant fibrosis (FIB4 F3-F4) | 32% | 33.3% |
Conclusions: Using sofosbuvir-free DAAs demonstrated SVR in all patients with frequent but not serious side effects, guaranteeing its efficacy and safety in the population studied with HCV and CKD-H.
Conflicts of interest: The authors have no conflicts of interest to declare.
